Business Description
Halozyme Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US40637H1095
Share Class Description:
FRA:RV7: Ordinary SharesDescription
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.44 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 3.32 | |||||
| Debt-to-EBITDA | 2.59 | |||||
| Interest Coverage | 25.41 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 4.27 | |||||
| Beneish M-Score | -2.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 48.4 | |||||
| 3-Year EBITDA Growth Rate | 46.1 | |||||
| 3-Year EPS without NRI Growth Rate | 30.1 | |||||
| 3-Year FCF Growth Rate | 95.2 | |||||
| 3-Year Book Growth Rate | -16.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 44.78 | |||||
| Future 3-5Y Total Revenue Growth Rate | 18.86 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.72 | |||||
| 9-Day RSI | 46.13 | |||||
| 14-Day RSI | 45.84 | |||||
| 6-1 Month Momentum % | -6.13 | |||||
| 12-1 Month Momentum % | 37.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.36 | |||||
| Quick Ratio | 9.15 | |||||
| Cash Ratio | 6.12 | |||||
| Days Inventory | 307.98 | |||||
| Days Sales Outstanding | 88.47 | |||||
| Days Payable | 31.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.1 | |||||
| Shareholder Yield % | -0.05 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 82.09 | |||||
| Operating Margin % | 50.35 | |||||
| Net Margin % | 41.43 | |||||
| FCF Margin % | 41.42 | |||||
| ROE % | 156.62 | |||||
| ROA % | 20.54 | |||||
| ROIC % | 30.11 | |||||
| ROC (Joel Greenblatt) % | 130.47 | |||||
| ROCE % | 27.86 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.9 | |||||
| Forward PE Ratio | 10.14 | |||||
| PE Ratio without NRI | 15.48 | |||||
| Shiller PE Ratio | 59.42 | |||||
| Price-to-Owner-Earnings | 17.73 | |||||
| PS Ratio | 6.58 | |||||
| PB Ratio | 13.5 | |||||
| Price-to-Free-Cash-Flow | 15.88 | |||||
| Price-to-Operating-Cash-Flow | 15.47 | |||||
| EV-to-EBIT | 13.93 | |||||
| EV-to-EBITDA | 11.97 | |||||
| EV-to-Forward-EBITDA | 9.25 | |||||
| EV-to-Revenue | 7.33 | |||||
| EV-to-Forward-Revenue | 5.99 | |||||
| EV-to-FCF | 17.69 | |||||
| Price-to-Projected-FCF | 2.02 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Earnings Yield (Greenblatt) % | 7.18 | |||||
| FCF Yield % | 6.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Halozyme Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 867.448 | ||
| EPS (TTM) (€) | 2.763 | ||
| Beta | 1.47 | ||
| Volatility % | 36.63 | ||
| 14-Day RSI | 45.84 | ||
| 14-Day ATR (€) | 0.902254 | ||
| 20-Day SMA (€) | 45.8635 | ||
| 12-1 Month Momentum % | 37.53 | ||
| 52-Week Range (€) | 30.78 - 58.18 | ||
| Shares Outstanding (Mil) | 127.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Halozyme Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Halozyme Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Halozyme Therapeutics Inc Frequently Asked Questions
What is Halozyme Therapeutics Inc(FRA:RV7)'s stock price today?
The current price of FRA:RV7 is €46.13. The 52 week high of FRA:RV7 is €58.18 and 52 week low is €30.78.
When is next earnings date of Halozyme Therapeutics Inc(FRA:RV7)?
The next earnings date of Halozyme Therapeutics Inc(FRA:RV7) is 2025-02-20 Est..
Does Halozyme Therapeutics Inc(FRA:RV7) pay dividends? If so, how much?
Halozyme Therapeutics Inc(FRA:RV7) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers